canada clinical guidance

Polycystic ovary syndrome (PCOS)

A Canadian clinical summary of polycystic ovary syndrome (pcos), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Diagnosis and management of polycystic ovarian syndrome. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CMAJ PCOS

Source-attributed clinical priorities

  • Confirm ovulatory dysfunction and clinical or biochemical androgen excess while excluding pregnancy and important endocrine mimics.
  • Assess metabolic, cardiovascular, endometrial, fertility, sleep and mental-health consequences across the lifespan.
  • Match cycle protection, androgen-symptom, metabolic and fertility treatment to goals, contraindications and pregnancy plans.
  • Use the applicable age-specific diagnostic criteria and avoid overdiagnosis soon after menarche.
sources for this section:CMAJ PCOS

Practical assessment and management workflow

1
Document cycle pattern, hirsutism or acne, weight trajectory, sleep, fertility and medication use.
2
Exclude pregnancy, thyroid disease, hyperprolactinemia and nonclassic adrenal or androgen-secreting disease when indicated.
3
Assess glucose, cardiovascular risk, endometrial protection, mood and sleep apnea.
4
Match cycle regulation, androgen treatment, metabolic care and fertility referral to the person鈥檚 priorities.
sources for this section:CMAJ PCOS

Safety, red flags and urgent escalation

  • Rapid virilization or markedly elevated androgen suggests a tumor or other urgent cause.
  • Prolonged amenorrhea requires endometrial-protection planning.
  • Review pregnancy and contraception before antiandrogen treatment.
sources for this section:CMAJ PCOS

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CMAJ PCOS

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CMAJ PCOS

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Medical Association JournalDiagnosis and management of polycystic ovarian syndromeCMAJ 2024;196:E85-E94; DOI 10.1503/cmaj.231251 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.